Tags

Type your tag names separated by a space and hit enter

Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study.

Abstract

BACKGROUND

The number of patients awaiting heart transplantation is increasing in proportion to the waiting period for a donor. Studies have shown that coenzyme Q10 (CoQ10) has a beneficial effect on patients with heart failure.

HYPOTHESIS

The purpose of the present double-blind, placebo-controlled, randomized study was to assess the effect of CoQ10 on patients with end-stage heart failure and to determine if CoQ10 can improve the pharmacological bridge to heart transplantation.

METHODS

A prospective double-blind design was used. Thirty-two patients with end-stage heart failure awaiting heart transplantation were randomly allocated to receive either 60 mg U/day of Ultrasome--CoQ10 (special preparation to increase intestinal absorption) or placebo for 3 months. All patients continued their regular medication regimen. Assessments included anamnesis with an extended questionnaire based partially on the Minnesota Living with Heart Failure Questionnaire, 6-min walk test, blood tests for atrial natriuretic factor (ANF) and tumor necrosis factor (TNF), and echocardiography.

RESULTS

Twenty-seven patients completed the study. The study group showed significant improvement in the 6-min walk test and a decrease in dyspnea, New York Heart Association (NYHA) classification, nocturia, and fatigue. No significant changes were noted after 3 months of treatment in echocardiography parameters (dimensions and contractility of cardiac chambers) or ANF and TNF blood levels.

CONCLUSIONS

The administration of CoQ10 to heart transplant candidates led to a significant improvement in functional status, clinical symptoms, and quality of life. However, there were no objective changes in echo measurements or ANF and TNF blood levels. Coenzyme Q10 may serve as an optional addition to the pharmacologic armamentarium of patients with end-stage heart failure. The apparent discrepancy between significant clinical improvement and unchanged cardiac status requires further investigation.

Links

  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Cardiothoracic Surgery, Heart-Lung Transplant Unit, Rabin Medical Center, Beilinson Campus, Potah Tikva, Israel. mariusby@yahoo.com

    , , , , , , ,

    Source

    Clinical cardiology 27:5 2004 May pg 295-9

    MeSH

    Adult
    Aged
    Atrial Natriuretic Factor
    Cardiotonic Agents
    Coenzymes
    Double-Blind Method
    Exercise Tolerance
    Female
    Heart Failure
    Heart Transplantation
    Humans
    Male
    Middle Aged
    Prospective Studies
    Quality of Life
    Recovery of Function
    Severity of Illness Index
    Tumor Necrosis Factor-alpha
    Ubiquinone
    Ultrasonography
    Waiting Lists

    Pub Type(s)

    Clinical Trial
    Journal Article
    Randomized Controlled Trial

    Language

    eng

    PubMed ID

    15188947

    Citation

    Berman, Marius, et al. "Coenzyme Q10 in Patients With End-stage Heart Failure Awaiting Cardiac Transplantation: a Randomized, Placebo-controlled Study." Clinical Cardiology, vol. 27, no. 5, 2004, pp. 295-9.
    Berman M, Erman A, Ben-Gal T, et al. Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clin Cardiol. 2004;27(5):295-9.
    Berman, M., Erman, A., Ben-Gal, T., Dvir, D., Georghiou, G. P., Stamler, A., ... Aravot, D. (2004). Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. Clinical Cardiology, 27(5), pp. 295-9.
    Berman M, et al. Coenzyme Q10 in Patients With End-stage Heart Failure Awaiting Cardiac Transplantation: a Randomized, Placebo-controlled Study. Clin Cardiol. 2004;27(5):295-9. PubMed PMID: 15188947.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Coenzyme Q10 in patients with end-stage heart failure awaiting cardiac transplantation: a randomized, placebo-controlled study. AU - Berman,Marius, AU - Erman,Arie, AU - Ben-Gal,Tuvia, AU - Dvir,Dan, AU - Georghiou,Georgios P, AU - Stamler,Alon, AU - Vered,Yaffa, AU - Vidne,Bernardo A, AU - Aravot,Dan, PY - 2004/6/11/pubmed PY - 2004/10/16/medline PY - 2004/6/11/entrez SP - 295 EP - 9 JF - Clinical cardiology JO - Clin Cardiol VL - 27 IS - 5 N2 - BACKGROUND: The number of patients awaiting heart transplantation is increasing in proportion to the waiting period for a donor. Studies have shown that coenzyme Q10 (CoQ10) has a beneficial effect on patients with heart failure. HYPOTHESIS: The purpose of the present double-blind, placebo-controlled, randomized study was to assess the effect of CoQ10 on patients with end-stage heart failure and to determine if CoQ10 can improve the pharmacological bridge to heart transplantation. METHODS: A prospective double-blind design was used. Thirty-two patients with end-stage heart failure awaiting heart transplantation were randomly allocated to receive either 60 mg U/day of Ultrasome--CoQ10 (special preparation to increase intestinal absorption) or placebo for 3 months. All patients continued their regular medication regimen. Assessments included anamnesis with an extended questionnaire based partially on the Minnesota Living with Heart Failure Questionnaire, 6-min walk test, blood tests for atrial natriuretic factor (ANF) and tumor necrosis factor (TNF), and echocardiography. RESULTS: Twenty-seven patients completed the study. The study group showed significant improvement in the 6-min walk test and a decrease in dyspnea, New York Heart Association (NYHA) classification, nocturia, and fatigue. No significant changes were noted after 3 months of treatment in echocardiography parameters (dimensions and contractility of cardiac chambers) or ANF and TNF blood levels. CONCLUSIONS: The administration of CoQ10 to heart transplant candidates led to a significant improvement in functional status, clinical symptoms, and quality of life. However, there were no objective changes in echo measurements or ANF and TNF blood levels. Coenzyme Q10 may serve as an optional addition to the pharmacologic armamentarium of patients with end-stage heart failure. The apparent discrepancy between significant clinical improvement and unchanged cardiac status requires further investigation. SN - 0160-9289 UR - https://www.unboundmedicine.com/medline/citation/15188947/Coenzyme_Q10_in_patients_with_end_stage_heart_failure_awaiting_cardiac_transplantation:_a_randomized_placebo_controlled_study_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0160-9289&date=2004&volume=27&issue=5&spage=295 DB - PRIME DP - Unbound Medicine ER -